Emerging from stealth mode, new immuno-oncology company Dotbio Pte. Ltd. closed an oversubscribed $5.6 million pre-series A round to accelerate development of its multifunctional and intracellular antibody therapies.

Oncusp Therapeutics Inc. has received IND clearance from the FDA to begin clinical trials with CUSP-06, a cadherin-6 (CDH6)-targeting antibody-drug conjugate designed for the treatment of multiple solid tumors. CDH6 is overexpressed in cancers including ovarian, renal, uterine, thyroid, lung, and cholangiocarcinoma. A phase I trial will pave the way for expansion in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.

Interleukin-4 (IL-4) plays an important role in regulating inflammation. While several antibody-based options targeting IL-4 have been reported, strategies based on small molecule inhibitors have proven difficult to find.

Approximately 100 years ago, Otto Warburg discovered that glucose consumption is elevated over ten-fold in cancer cells compared to normal...

Day One Biopharmaceuticals Inc. has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience...

Thryv Therapeutics Inc. has received FDA clearance of its IND application for THRV-1257 (THRYV-1257) for the treatment of advanced...

Delcath Systems Inc. reported that the FDA approved its Hepzato Kit for the treatment of adults with unresectable hepatic-dominant metastatic uveal melanoma (mUM). The FDA nod also triggered a second tranche of financing of approximately $35 million from a private placement in March.

Broncus Holding Corp. successfully completed a clinical study of the world’s first transbronchial radiofrequency ablation system for lung cancer treatment.